CYTO - Altamira Therapeutics Ltd. Total Debt to Capital

The price visualization on GURU.Markets demonstrates the total debt-to-equity ratio of Altamira Therapeutics (CYTO), which stands at 0.00. The company's finances depend on grants and investments in the study of ENT therapy methods. The business relies on an international supply network of polymers for RNA systems, which supports high profitability. An impeccable image and partner trust confirm the premium status of their technological platform.

This ratio determines the degree of the business's dependence on borrowed funds by comparing total liabilities to equity to assess financial stability. Analyzing the historical debt-to-equity ratio allows for a solvency stress test of Altamira Therapeutics (CYTO), which is critical when scaling the development of RNA sprays within the growing biosecurity and anti-allergy drug markets.